A study published Wednesday in the medical journal The Lancet showed that three drugs, including the anti-HIV drugs Lopinavir and Litonavir, were combined with standard care to show therapeutic effects in phase 2 clinical trials for new coronavirus infections with mild to moderate symptoms. But the researchers say further tests are needed to verify the efficacy.
The clinical trial was conducted by academics from the University of Hong Kong and other institutions. They recruited 127 adult patients diagnosed with the new coronavirus in hospitals in Hong Kong to participate in the trial. The three drugs used by the researchers included beta-1b interferon, lofinavir and litonavir, and ribavirin.
Patients were randomly assigned to two groups, one of which began using the above combination of drugs for two weeks within 7 days of developing symptoms of neo-coronavirus infection, and the control group was treated only with lopinavir and litonavir for the same period.
The results showed that the combination of drugs was safe and that the use of the combination of drugs was more effective in reducing the detoxification period of the new coronavirus in patients than with only lopinavir and litonavir serotonin for patients with mild to moderate symptoms. It took an average of 7 days for patients with triple-drug therapy to reduce the virus to undetectable levels, while patients who used only Lopinavir and Litonavir alone took an average of 12 days.
The team said the trials at this stage did not include patients with severe illnesses, and that three future clinical trials were needed to verify whether the drug combination was clinically reliable.